Inovio Pharmaceuticals, Inc. News (NASDAQ:INO)

DateTimeSource
Headline
04/11/20188:00AMGLOBEInovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
PLYMOUTH MEETING, Pa. and OSLO, Norway, April 11, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and CEPI – the Coalition for Epidemic Preparedness Innovations – today announced a partnership under which Inovio will develop vaccine candidates against Lassa fever and Middle East Respiratory Syndrome... More...>>
04/02/20188:00AMGLOBEInovio Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference
PLYMOUTH MEETING, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, Inovio’s President & CEO, will provide a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference, being held April 8-10 in Monte Carlo, Monaco. Presentation... More...>>
03/20/20188:00AMGLOBEInovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
PLYMOUTH MEETING, Pa., March 20, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced it has closed an agreement providing ApolloBio Corp. (NEEQ:430187) with the exclusive right to develop, manufacture and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat precancers... More...>>
03/14/20184:05PMGLOBEInovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results
PLYMOUTH MEETING, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2017. Total revenue was $8.8 million and $42.2 million for the quarter and year ended December 31, 2017, respectively, as compared to $8.5... More...>>
03/14/20188:00AMGLOBEInovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection
PLYMOUTH MEETING, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis B virus (HBV) infection was safe, well-tolerated and generated virus-specific T cells, including CD8+ killer T cells, meeting... More...>>
03/12/20188:00AMGLOBEInovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 2018
PLYMOUTH MEETING, Pa., March 12, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 fourth quarter and year end financial results on Wednesday, March 14, 2018 at 4:30 p.m. ET. A live and archived version of the audio... More...>>
02/12/20188:00AMGLOBEInovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Mala...
PLYMOUTH MEETING, Pa., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the company is collaborating with The Wistar Institute to advance two novel SynCon® vaccine programs against tuberculosis (TB) and malaria, fully funded by more than $4.6 million in total grants from... More...>>
02/05/20188:45AMGLOBEInovio Pharmaceuticals to Participate in Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences: BIO CEO & Investor ConferencePresentationDr. J. Joseph Kim, President & CEOFebruary 13, 2018, 2:15 PM ETNew York... More...>>
01/22/20188:00AMGLOBEInovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1...
PLYMOUTH MEETING, Pa., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Inovio’s synthetic vaccine approach using a collection of synthetic DNA antigens generated broad protective antibody responses against all major deadly strains of H1 influenza viruses from the last... More...>>
01/17/20188:00AMGLOBEInovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for ...
PLYMOUTH MEETING, Pa., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. David B. Weiner, its co-founder; and Dr. Jian Yan, the company’s Lead Antigen Designer, have been selected as two of the “Top 20 Translational Researchers” for the year 2016 by the editors of... More...>>
01/09/20188:00AMGLOBEInovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Eval...
Advances development of Inovio’s ASPIRE™ (Antigen SPecific Immune REsponses) immunotherapy platform as a foundation for novel combination regimen approachesEngages the Parker Institute’s extensive immunotherapy expertise and academic and research network on studies that have the potential to address cancers with... More...>>
01/08/20188:00AMGLOBEInovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squa...
PLYMOUTH MEETING, Pa., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has received a milestone payment from MedImmune as MEDI0457 (formerly called INO-3112 which MedImmune in-licensed from Inovio) in combination with durvalumab (MEDI4736) satisfactorily completed the phase... More...>>
01/02/20188:00AMGLOBEInovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
PLYMOUTH MEETING, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it entered an amended agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat pre-cancers... More...>>
12/11/20178:00AMGLOBEInovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development
PLYMOUTH MEETING, Pa., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has promoted Dr. Laurent Humeau to Senior Vice President, Research & Development, reporting to Dr. J. Joseph Kim, Inovio’s President & CEO. Dr. Humeau joined Inovio in 2014 as Vice President, R&D. Dr. Humeau... More...>>
12/06/20178:00AMGLOBEInovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors
PLYMOUTH MEETING, Pa., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Wendy Yarno has been elected to the company's Board of Directors. Wendy Yarno has over 25 years of experience in the pharmaceutical industry highlighted by her tenure at Merck & Co. where she served... More...>>
11/29/20178:00AMGLOBEInovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clini...
PLYMOUTH MEETING, Pa., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that post-hoc analysis of data generated from its phase 2b trial of VGX-3100 identified immune correlates and biomarker signatures predictive of treatment success.  VGX-3100, Inovio’s lead product now in... More...>>
11/27/20178:00AMGLOBEInovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor a...
PLYMOUTH MEETING, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase) cancer immunotherapy in combination with a checkpoint inhibitor in preclinical tumor model. The combination therapies resulted... More...>>
11/10/201710:27AMGLOBEInovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference
PLYMOUTH MEETING, Pa., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that two of its cancer immunotherapies demonstrated antigen-specific T-cell stimulation in phase 1 studies. INO-3112 (now called MEDI0457), an investigational T-cell activation immunotherapy that targets cancers... More...>>
11/09/20178:00AMGLOBEInovio Pharmaceuticals to Participate In Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences: Stifel 2017 Healthcare ConferencePresentation and 1x1 meetingsDr. Niranjan Y. Sardesai, COO11:45 AM ET, November 15, 2017New... More...>>
11/08/20174:05PMGLOBEInovio Pharmaceuticals Reports 2017 Third Quarter Financial Results
PLYMOUTH MEETING, Pa., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended September 30, 2017. Total revenue was $2.6 million for the three months ended September 30, 2017, compared to $12.5 million for the same period in 2016. Total operating... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V:us D:20180420 02:49:43